Journal of The Egyptian Society of Nephrology and Transplantation

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 20  |  Issue : 3  |  Page : 151--156

Evaluation of chemokine receptor 2 polymorphism in patients with end-stage renal disease


Manal M Alkady1, Phebe L Abdel-Messeih1, Hussein S El-Fishawy2, Eman M Eltahlawy3 
1 Assistant Professor of Clinical and Chemical Pathology, Health Radiation Research Department, National Center for Radiation Research and Technology, Atomic Energy Authority, Cairo, Egypt
2 Assisstant Professor of Nephrology and Internal Medicine, Depatment of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
3 Professor of Public Health, Department of Enviromental Sciences Research, National Research Center, Cairo, Egypt

Correspondence Address:
Dr. Manal M Alkady
Department of Health Radiation Research, National Center for Radiation Research and Technology, Atomic Energy Authority, P.O. Box 29, Nasr City, Cairo
Egypt

Background The inflammatory state accompanying end-stage renal disease (ESRD) is hallmarked by renal infiltration of monocytes/macrophages, which are the major source of chemokines and chemokine receptors. We aimed to determine the frequency and association of chemokine receptor 2 (CCR2)-V64I polymorphism in patients with ESRD. Patients and methods A total of 35 patients attending the hemodialysis unit and 21 healthy controls were recruited in this study. The PCR-restriction fragment length polymorphism technique was used to assess genotype frequencies of CCR2-V64I. Results The frequency of genotypes GG, AG, and AA in patient group was 65.7, 25.7, and 8.6%, respectively, in comparison with 81.0, 14.3, and 4.8%, respectively, in the control group. Therefore, the patient group showed higher frequency of AG and AA genotypes and a lower frequency of GG genotype than the control group but this difference was not significant. The frequencies of A and G alleles did not show a significant difference between the two groups. The frequencies of G and A alleles were 78.6 and 21.4%, respectively, in the patient group in comparison with 88.1 and 11.9%, respectively, in the controls. Patients carrying the genotypes AA and G/A showed rapid progression to ESRD than those with genotype G/G. No significant association was found between the occurrence of polymorphism and the presence of hypertension or diabetes mellitus. Conclusion The CCR2-V64I gene polymorphism may play a role in the pathogenesis and severity of ESRD in Egyptian patients. To uncover this role, further analyses should be carried out on larger population-based studies.


How to cite this article:
Alkady MM, Abdel-Messeih PL, El-Fishawy HS, Eltahlawy EM. Evaluation of chemokine receptor 2 polymorphism in patients with end-stage renal disease.J Egypt Soc Nephrol Transplant 2020;20:151-156


How to cite this URL:
Alkady MM, Abdel-Messeih PL, El-Fishawy HS, Eltahlawy EM. Evaluation of chemokine receptor 2 polymorphism in patients with end-stage renal disease. J Egypt Soc Nephrol Transplant [serial online] 2020 [cited 2020 Dec 6 ];20:151-156
Available from: http://www.jesnt.eg.net/article.asp?issn=1110-9165;year=2020;volume=20;issue=3;spage=151;epage=156;aulast=Alkady;type=0